BMJ open · 2026
Lower versus standard dose-intensity continuous renal replacement therapy: a protocol for a systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lumlertgul Nuttha, Kusirisin Prit, Kung Janice Y, Duquette D'Arcy, Fujii Tomoko, Zarbock Alexander, Wald Ron, Bagshaw Sean M
Аннотация
INTRODUCTION: The 2012 Kidney Diseases Improving Global Outcomes clinical practice guideline recommends prescribing continuous renal replacement therapy (CRRT) doses in patients with acute kidney injury (AKI) between 20 and 25 mL/kg/hour, with a need to consider further augmentation to 25-30 mL/kg/hour. Observational data have shown that lower-dose CRRT (<20 mL/kg/hour) may be tolerated and reduce adverse effects related to higher or guideline-directed standard dose-intensity CRRT. We aim to conduct a systematic review and meta-analysis of current evidence regarding tolerability, safety and clinical outcomes of lower CRRT dose-intensity compared with guideline-directed standard dose-intensity CRRT.
METHODS AND ANALYSIS: Ovid MEDLINE, Ovid Embase, CINAHL and Cochrane Library will be searched for studies from inception to present. We will evaluate the risk of bias using the modified Cochrane tool for randomised controlled trials and the Cochrane Risk of Bias In Non-randomised Studies-of Interventions tool for cohort studies. Two reviewers will independently complete study selection, data extraction and bias assessment. Inclusion criteria will be randomised controlled trials and observational studies (cohort) including patients with AKI receiving CRRT. The exposure will be lower dose-intensity CRRT (<20 mL/kg/hour) compared with guideline-directed standard dose-intensity CRRT (≥20-40 mL/kg/hour). Outcomes will include intensive care unit and hospital mortality, dialysis duration and dependence and indicators of metabolic control. Pooled random-effect meta-analysis ORs with 95% CIs will be reported, if able.
ETHICS AND DISSEMINATION: Ethics approval is not required as primary data will not be collected. Findings of this review will be disseminated through peer-related publication.
PROSPERO REGISTRATION NUMBER: CRD420251135606.
METHODS AND ANALYSIS: Ovid MEDLINE, Ovid Embase, CINAHL and Cochrane Library will be searched for studies from inception to present. We will evaluate the risk of bias using the modified Cochrane tool for randomised controlled trials and the Cochrane Risk of Bias In Non-randomised Studies-of Interventions tool for cohort studies. Two reviewers will independently complete study selection, data extraction and bias assessment. Inclusion criteria will be randomised controlled trials and observational studies (cohort) including patients with AKI receiving CRRT. The exposure will be lower dose-intensity CRRT (<20 mL/kg/hour) compared with guideline-directed standard dose-intensity CRRT (≥20-40 mL/kg/hour). Outcomes will include intensive care unit and hospital mortality, dialysis duration and dependence and indicators of metabolic control. Pooled random-effect meta-analysis ORs with 95% CIs will be reported, if able.
ETHICS AND DISSEMINATION: Ethics approval is not required as primary data will not be collected. Findings of this review will be disseminated through peer-related publication.
PROSPERO REGISTRATION NUMBER: CRD420251135606.